Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
Mirikizumab consistently demonstrated disease clearance across induction, maintenance, and long-term studies. The attainment of disease clearance was associated with greater improvement in PROs, and early achievement of disease clearance was associated with better long-term outcomes, including clinical remission, corticosteroid-free remission, endoscopic and histological outcomes, reduced stool frequency, and rectal bleeding.
Authors
- Jean‐Frédéric Colombel (ORCID: https://orcid.org/0000-0001-6472-249X)
- Britta Siegmund (ORCID: https://orcid.org/0000-0002-0055-958X)
- Jianmin Wu (ORCID: https://orcid.org/0000-0002-6526-7967)
- Vipul Jairath (ORCID: https://orcid.org/0000-0002-1092-0033)
- Jerome Paulissen
- Fernando Magro (ORCID: https://orcid.org/0000-0003-2634-9668)
- Taku Kobayashi (ORCID: https://orcid.org/0000-0002-2073-4234)
- Baojin Zhu (ORCID: https://orcid.org/0000-0003-4462-1856)
- Richard Moses
- Isabel Redondo
- Corey A. Siegel
- Agni Dhanabal
Institutions
- Western University (CA)
- Dartmouth–Hitchcock Medical Center (US)
- Eli Lilly (United States) (US)
- Universidade do Porto (PT)
- Hospital de São João (PT)
- Humboldt-Universität zu Berlin (DE)
- Syneos Health (United States) (US)
- Eli Lilly (Spain) (ES)
- Centre for Health Technology and Services Research (PT)
- Kitasato Institute Hospital (JP)
- Kitasato University (JP)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Crohn s and Colitis
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1093/ecco-jcc/jjaf124
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00